Emerging biological therapies for the treatment of age-related macular degeneration

References

• Congdon N, O’Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. Apr 2004;122(4):477–485.
   PubMed Web of Science ®Google Scholar
• Friedman DS, O’Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. Apr 2004;122(4):564–572.
   PubMed Web of Science ®Google Scholar
• Palejwala NV, Jia Y, Gao SS, et al. DETECTION OF NONEXUDATIVE CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION WITH OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina. Nov 2015;35(11):2204–2211.
   PubMed Web of Science ®Google Scholar
• Bailey ST, Thaware O, Wang J, et al. Detection of Nonexudative Choroidal Neovascularization and progression to Exudative Choroidal Neovascularization using OCT Angiography. Ophthalmol Retina. Aug 2019;3(8):629–636.
   PubMedGoogle Scholar
• Group A-REDSR. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. Oct 2001;119(10):1417–1436.
   PubMedGoogle Scholar
• Chew EY, Clemons TE, Sangiovanni JP, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol Feb 2014;132(2):142–149.
   PubMed Web of Science ®Google Scholar
• Schultz NM, Braunack-Mayer L, Schwartz J, et al. The patient experience: symptoms and impact of dry age-related macular degeneration. Ophthalmol Ther. Jan 29 2021 10 1 151–164
   PubMed Web of Science ®Google Scholar
• Evans JR, Lawrenson JG Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. Nov 14 2012;11:Cd000254.
   PubMed Web of Science ®Google Scholar
• Evans JR, Lawrenson JG Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev. Jul 30 2017;7(7):Cd000253.
   PubMedGoogle Scholar
• Klein R, Wang Q, Klein BE, et al. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. Jan 1995;36(1):182–191.
   PubMed Web of Science ®Google Scholar
• Finger RP, Puth MT, Schmid M, et al. Lifetime outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. JAMA Ophthalmol. Oct 15 2020;138(12):1–7.
   Web of Science ®Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. Feb 2014;2(2):e106–16.
   PubMed Web of Science ®Google Scholar
• Awh CC, Hawken S, Zanke BW Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the age-related eye disease study. Ophthalmology. Jan 2015;122(1):162–169.
   PubMed Web of Science ®Google Scholar
• Assel MJ, Li F, Wang Y, et al. Genetic Polymorphisms of CFH and ARMS2 do not predict response to antioxidants and zinc in patients with age-related macular degeneration: independent statistical evaluations of data from the age-related eye disease study. Ophthalmology. Mar 2018;125(3):391–397.
   PubMed Web of Science ®Google Scholar
• Van Asten F, Chiu CY, Agrón E, et al. No CFH or ARMS2 interaction with omega-3 fatty acids, low versus high zinc, or β-carotene versus lutein and zeaxanthin on progression of age-related macular degeneration in the age-related eye disease study 2: age-related eye disease study 2 report no. 18. Ophthalmology. Nov 2019;126(11):1541–1548.
   PubMed Web of Science ®Google Scholar
• Fursova A, Gesarevich OG, Gonchar AM, et al. [Dietary supplementation with bilberry extract prevents macular degeneration and cataracts in senesce-accelerated OXYS rats]. Adv Gerontol. 2005;16:76–79.
   PubMedGoogle Scholar
• Wang Y, Zhao L, Lu F, et al. Retinoprotective effects of Bilberry Anthocyanins via Antioxidant, Anti-Inflammatory, and Anti-Apoptotic mechanisms in a visible light-induced retinal degeneration model in pigmented rabbits. Molecules. Dec 14 2015;20(12):22395–22410.
   PubMed Web of Science ®Google Scholar
• Osada H, Okamoto T, Kawashima H, et al. Neuroprotective effect of bilberry extract in a murine model of photo-stressed retina. PLoS One. 2017;12(6):e0178627.
   PubMed Web of Science ®Google Scholar
• Kanavi MR, Darjatmoko S, Wang S, et al. The sustained delivery of resveratrol or a defined grape powder inhibits new blood vessel formation in a mouse model of choroidal neovascularization. Molecules. Oct 30 2014;19(11):17578–17603.
   PubMed Web of Science ®Google Scholar
• Patel AK, Davis A, Rodriguez ME, et al. Protective effects of a grape-supplemented diet in a mouse model of retinal degeneration. Nutrition. 2016;32(3):384–390.
   PubMed Web of Science ®Google Scholar
• Yang L, Xian D, Xiong X, et al. Proanthocyanidins against oxidative stress: from molecular mechanisms to clinical applications. Biomed Res Int. 2018 03 12 2018; 2018:8584136.
   PubMed Web of Science ®Google Scholar
• Souied EH, Delcourt C, Querques G, et al. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the nutritional AMD treatment 2 study. Ophthalmology. Aug 2013;120(8):1619–1631.
   PubMed Web of Science ®Google Scholar
• Souied EH, Aslam T, Garcia-Layana A, et al. Omega-3 fatty acids and age-related macular degeneration. Ophthalmic Res. 2015;55(2):62–69.
   PubMed Web of Science ®Google Scholar
• Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina. Mar 2013;33(3):498–507.
   PubMed Web of Science ®Google Scholar
• Sparrow JR, Gregory-Roberts E, Yamamoto K, et al. The bisretinoids of retinal pigment epithelium. Prog Retin Eye Res. Mar 2012;31(2):121–135.
   PubMed Web of Science ®Google Scholar
• Radu RA, Hu J, Jiang Z, et al. Bisretinoid-mediated complement activation on retinal pigment epithelial cells is dependent on complement factor H haplotype. J Biol Chem. Mar 28 2014;289(13):9113–9120.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. Dec 30 2004;351(27):2805–2816.
   PubMed Web of Science ®Google Scholar
• Kim LA, D’Amore PA A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol. Aug 2012;181(2):376–379.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. Oct 5 2006;355(14):1419–1431.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. Oct 5 2006;355(14):1432–1444.
   PubMed Web of Science ®Google Scholar
• Df M, Mg M, Gs Y, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. May 19 2011;364(20):1897–1908.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. Jul 2012;119(7):1399–1411.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. Dec 2012;119(12):2537–2548.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. Jan 2020;127(1):72–84.
   PubMed Web of Science ®Google Scholar
• Smith AG, Kaiser PK Emerging treatments for wet age-related macular degeneration. Expert Opin Emerg Drugs. Mar 2014;19(1):157–164.
   PubMed Web of Science ®Google Scholar
• Koh A, Lee WK, Chen L-J, et al. EVEREST STUDY: efficacy and Safety of Verteporfin Photodynamic Therapy in Combination with Ranibizumab or Alone Versus Ranibizumab Monotherapy in Patients with Symptomatic Macular Polypoidal Choroidal Vasculopathy. RETINA. 2012;32(8) 8
   Web of Science ®Google Scholar
• Eye health supplements market size, trends, shares, insights and forecast - 2027. Coherent Market Insights. cited Feb 5, 2021, https://www.coherentmarketinsights.com/market-insight/eye-health-supplements-market-3791
   Google Scholar
• Ng W U.S. top multivitamin brands based on sales, 2019. Statista. Accessed Feb 5, 2021, https://www.statista.com/statistics/195561/leading-us-vitamin-brands-based-on-sales/
   Google Scholar
• ReportLinker. Age-Related Macular Degeneration: global Drug Forecast and Market Analysis to 2028. GlobeNewswire News Room. cited 2021 Feb 5, https://www.globenewswire.com/news-release/2020/04/24/2021766/0/en/Age-Related-Macular-Degeneration-Global-Drug-Forecast-and-Market-Analysis-to-2028.html
   Google Scholar
• Inc RP. Regeneron reports fourth quarter and full year 2020 financial and operating results. [cited 2021 Feb 6]. Available from: https://www.prnewswire.com/news-releases/regeneron-reports-fourth-quarter-and-full-year-2020-financial-and-operating-results-301222814.html
   Google Scholar
• J M. Q2-2020 ophthalmic company earnings: alimera, hoya, lumibird, roche, Novartis, j&j vision. Market Scope. [cited 2021 Feb 7]. Available from: https://www.market-scope.com/pages/news/4707/q2-2020-ophthalmic-company-earnings-alimera-hoya-lumibird-roche-novartis-jandj-vision
   Google Scholar
• Ca J, Tp J, Walport M, et al. Immunobiology: the Immune System in Health and Disease. 5th edition. 2001. New York: Garland Science, immunity. Tcsai.
   Google Scholar
• Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. Sep 2010;11(9):785–797.
   PubMed Web of Science ®Google Scholar
• Kolev M, Le Friec G, Kemper C Complement–tapping into new sites and effector systems. Nat Rev Immunol. 2014:811-20. vol. 12.
   Google Scholar
• Schramm EC, Clark SJ, Triebwasser MP, et al. Genetic variants in the complement system predisposing to age-related macular degeneration: a review. Mol Immunol. Oct 2014;61(2):118–125.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Schmidt-Erfurth U, Van Lookeren Campagne M, et al. THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET. Retina. May 2017;37(5):819–835.
   PubMed Web of Science ®Google Scholar
• Fritsche LG, Fariss RN, Stambolian D, et al. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet. 2014;15:151–171. 1
   PubMedGoogle Scholar
• Hollyfield JG, Bonilha VL, Rayborn ME, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med. Feb 2008;14(2):194–198.
   PubMed Web of Science ®Google Scholar
• Ding JD, Kelly U, Groelle M, et al. The role of complement dysregulation in AMD mouse models. Adv Exp Med Biol. 2014;801:213–219.
   PubMed Web of Science ®Google Scholar
• Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: a Randomized Phase 2 Trial. Ophthalmology. Feb 2020;127(2):186–195.
   PubMed Web of Science ®Google Scholar
• Kassa E, Ciulla TA, Hussain RM, et al. Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. Apr 2019;19(4):335–342.
   PubMed Web of Science ®Google Scholar
• Yehoshua Z, Ca DAGF, Rp N et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. Mar 2014;121(3):693–701.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology. 2021 April. doi:10.1016/j.ophtha.2020.08.027
   Google Scholar
• Di Caprio R, Lembo S, Di Costanzo L, et al. Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediators Inflamm. 2015;2015:329418.
   PubMed Web of Science ®Google Scholar
• Al-Zamil WM, Yassin SA Recent developments in age-related macular degeneration: a review. Clin Interv Aging. 2017;12:1313–1330.
   PubMed Web of Science ®Google Scholar
• Lin MK, Yang J, Hsu CW, et al. HTRA1, an age-related macular degeneration protease, processes extracellular matrix proteins EFEMP1 and TSP1. Aging Cell. Aug 2018;17(4):e12710.
   PubMed Web of Science ®Google Scholar
• Iejima D, Nakayama M, Iwata T HTRA1 overexpression induces the exudative form of age-related macular degeneration. J Stem Cells. 2015;10(3):193–203.
   PubMedGoogle Scholar
• Xu L, Kong L, Wang J, et al. Stimulation of AMPK prevents degeneration of photoreceptors and the retinal pigment epithelium. Proc Natl Acad Sci U S A. Oct 9 2018;115(41):10475–10480.
   PubMed Web of Science ®Google Scholar
• Brown EE, Ball JD, Chen Z, et al. The common antidiabetic drug metformin reduces odds of developing age-related macular degeneration. Invest Ophthalmol Vis Sci. Apr 1 2019;60(5):1470–1477.
   PubMed Web of Science ®Google Scholar
• Chen YY, Shen YC, Lai YJ, et al. Association between metformin and a lower risk of age-related macular degeneration in patients with type 2 diabetes. J Ophthalmol. 2019;2019:1649156.
   PubMed Web of Science ®Google Scholar
• Stewart JM, Lamy R, Wu F, et al. Relationship between oral metformin use and age-related macular degeneration. Ophthalmol Retina. Nov 2020;4(11):1118–1119.
   PubMedGoogle Scholar
• Blitzer AL, Ham SA, Colby KA, et al. Association of metformin use with age-related macular degeneration: a case-control study. JAMA Ophthalmol. 2021;139(3):302–309.
   PubMed Web of Science ®Google Scholar
• Hanus J, Zhao F, Wang S Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol. Jan 2016;100(1):122–127.
   PubMed Web of Science ®Google Scholar
• Hussain RM, Gregori NZ, Ciulla TA, et al. Pharmacotherapy of retinal disease with visual cycle modulators. Expert Opin Pharmacother. Apr 2018;19(5):471–481.
   PubMed Web of Science ®Google Scholar
• Alkeus Pharmaceuticals I. ALK-001 halts vision loss in a mouse model of stargardt disease. [cited2021 Feb 10]. Available from: http://www.alkeuspharma.com/preclinical.html
   Google Scholar
• Scholl HP, Tsang SH, Kay CN, et al. Stargardt disease ALK-001 phase 2 clinical trial: 12-month interim data. Invest Ophthalmol Vis Sci. 2019;60(9):1336.
   PubMed Web of Science ®Google Scholar
• Ding K, Shen J, Hafiz Z, et al. AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. J Clin Invest. Aug 13 2019;129(11):4901–4911.
   PubMed Web of Science ®Google Scholar
• Richardson PM Ciliary neurotrophic factor: a review. Pharmacol Ther. Aug 1994;63(2):187–198.
   PubMed Web of Science ®Google Scholar
• LaVail MM, Yasumura D, Matthes MT, et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci. Mar 1998;39(3):592–602.
   PubMed Web of Science ®Google Scholar
• LaVail MM, Unoki K, Yasumura D, et al. Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc Natl Acad Sci U S A. Dec 1 1992;89(23):11249–11253.
   PubMed Web of Science ®Google Scholar
• Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(15):6241–6245.
   PubMed Web of Science ®Google Scholar
• Kusari J, Padillo E, Zhou SX, et al. Effect of brimonidine on retinal and choroidal neovascularization in a mouse model of retinopathy of prematurity and laser-treated rats. Invest Ophthalmol Vis Sci. Jul 20 2011;52(8):5424–5431.
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Patel SS, Boyer DS, et al. PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina. Jan 1 2021;41(1):144–155.
   PubMed Web of Science ®Google Scholar
• Al-Khersan H, Hussain RM, Ciulla TA, et al. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother. Oct 2019;20(15):1879–1891.
   PubMed Web of Science ®Google Scholar
• Patel SS, Janer D, Miller B, et al. Updated Results of Phase 1b Study of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate with Extended Durability, in wAMD, DME, and RVO. Invest Ophthalmol Vis Sci. 2020;61(7):4286.
   Google Scholar
• Luu KT, Seal JR, Attar M A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic model of abicipar pegol and vascular endothelial growth factor inhibition. J Pharmacol Exp Ther. May 2020;373(2):184–192.
   PubMed Web of Science ®Google Scholar
• Callanan D, Kunimoto D, Maturi RK, et al. Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration. J Ocul Pharmacol Ther. Dec 2018;34(10):700–709.
   PubMed Web of Science ®Google Scholar
• Kunimoto D, Yoon YH, Wykoff CC, et al. Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study. Ophthalmology. Oct 2020;127(10):1331–1344.
   PubMed Web of Science ®Google Scholar
• Hussain RM, Weng CY, Wykoff CC, et al. Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. Sep 2020;20(9):999–1008.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Boyer DS, Antoszyk AN, et al. Phase 1 study of OPT-302 inhibition of vascular endothelial growth factors C and D for neovascular age-related macular degeneration. Ophthalmol Retina. Mar 2020;4(3):250–263.
   PubMedGoogle Scholar
• Sharma A, Reddy P, Kuppermann BD, et al. Biosimilars in ophthalmology: “Is there a big change on the horizon?”. Clin Ophthalmol. 2018;12:2137–2143.
   PubMed Web of Science ®Google Scholar
• Sharma S, Khan M, Chaturvedi A A multicenter, retrospective study (RE-ENACT 2) on the use of razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration. Ophthalmol Ther. Mar 2020;9(1):103–114.
   PubMed Web of Science ®Google Scholar
• Pipeline OTa. Graybug. cited Feb 1, 2021, https://www.graybug.vision/our-technologies-and-pipeline/#gb102
   Google Scholar
• Graybug vision reports preliminary topline results from phase 2b ALTISSIMO Trial. 2021. cited 2021 Apr 11. https://investors.graybug.vision/node/7041/pdf
   Google Scholar
• Sharma A, Kumar N, Kuppermann BD, et al. Faricimab: expanding horizon beyond VEGF. Eye (Lond). May 2020;34(5):802–804.
   PubMed Web of Science ®Google Scholar
• Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: the STAIRWAY Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. Sep 1 2020;138(9):964–972.
   PubMed Web of Science ®Google Scholar
• Sahni J, Dugel PU, Patel SS, et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol. Sep 1 2020;138(9):955–963.
   PubMed Web of Science ®Google Scholar
• Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration. Roche. cited Feb 1, 2021, https://www.roche.com/media/releases/med-cor-2021-01-25.htm
   Google Scholar
• Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology. Aug 2019;126(8):1141–1154.
   PubMed Web of Science ®Google Scholar
• Khanani AM, Callanan D, Dreyer R, et al. End-of-study results for the ladder phase 2 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina. Nov 18 2020;doi:10.1016/j.oret.2020.11.004
   Google Scholar
• Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration. Roche. cited 2021 Feb 1, https://www.roche.com/media/releases/med-cor-2020-07-22b.htm
   Google Scholar
• AKST4290: targeting Eotaxin. Alkahest. cited 2021 Feb 1, https://www.alkahest.com/pipeline/akst4290/
   Google Scholar
• Sirivichayakul S, Kanchanatawan B, Thika S, et al. Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), is a major contributor to cognitive decline in normal people and to executive, memory, and sustained attention deficits, formal thought disorders, and Psychopathology in Schizophrenia Patients. Neurotox Res. Jan 2019;35(1):122–138.
   PubMed Web of Science ®Google Scholar
• Wang H, Han X, Gambhir D, et al. Retinal Inhibition of CCR3 Induces Retinal Cell Death in a Murine Model of Choroidal Neovascularization. PLoS One. 2016;11(6):e0157748.
   PubMed Web of Science ®Google Scholar
• Smith A A glossary for stem-cell biology.
   Google Scholar
• Qu L, Gao L, Xu H, et al. Combined transplantation of human mesenchymal stem cells and human retinal progenitor cells into the subretinal space of RCS rats. Sci Rep. Mar 15 2017;7(1):199.
   PubMedGoogle Scholar
• Mead B, Bone Marrow-Derived TS Mesenchymal stem cells-derived exosomes promote survival of retinal ganglion cells through miRNA-dependent mechanisms. Stem Cells Transl Med. Apr 2017;6(4):1273–1285.
   PubMed Web of Science ®Google Scholar
• Evans MJ, Kaufman MH Establishment in culture of pluripotential cells from mouse embryos. Nature. Jul 9 1981;292(5819):154–156.
   PubMed Web of Science ®Google Scholar
• Pera MF, Reubinoff B, Trounson A Human embryonic stem cells. J Cell Sci. Jan 2000;113 (Pt 1):5–10.
   PubMed Web of Science ®Google Scholar
• King NM, Perrin J Ethical issues in stem cell research and therapy. Stem Cell Res Ther. 2014;5(4):85.
   PubMedGoogle Scholar
• Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. Dec 21 2007;318(5858):1917–1920.
   PubMed Web of Science ®Google Scholar
• Hu C, Li LJ Improving the Reprogramming Efficiency of Somatic Cells to Induced Pluripotent Stem Cells. Crit Rev Eukaryot Gene Expr. 2015;25(4):323–334.
   PubMed Web of Science ®Google Scholar
• Gore A, Li Z, Fung H-L, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011;471(7336):63–67.
   PubMed Web of Science ®Google Scholar
• Golestaneh N, Chu Y, Xiao YY, et al. Dysfunctional autophagy in RPE, a contributing factor in age-related macular degeneration. Cell Death Dis. Jan 5 2017;8(1):e2537.
   PubMedGoogle Scholar
• Lu B, Malcuit C, Wang S, et al. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells. Sep 2009;27(9):2126–2135.
   PubMed Web of Science ®Google Scholar
• Aoki H, Hara A, Nakagawa S, et al. Embryonic stem cells that differentiate into RPE cell precursors in vitro develop into RPE cell monolayers in vivo. Exp Eye Res. Feb 2006;82(2):265–274.
   PubMed Web of Science ®Google Scholar
• Kokkinaki M, Sahibzada N, Golestaneh N Human induced pluripotent stem-derived retinal pigment epithelium (RPE) cells exhibit ion transport, membrane potential, polarized vascular endothelial growth factor secretion, and gene expression pattern similar to native RPE. Stem Cells. 2011;29(5):825–835.
   PubMed Web of Science ®Google Scholar
• Kamao H, Mandai M, Okamoto S, et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports. Feb 11 2014;2(2):205–218.
   PubMed Web of Science ®Google Scholar
• Song WK, Park KM, Kim HJ, et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Reports. May 12 2015;4(5):860–872.
   PubMed Web of Science ®Google Scholar
• Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. Feb 25 2012;379(9817):713–720.
   PubMed Web of Science ®Google Scholar
• Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. Feb 7 2015;385(9967):509–516.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu HW, Wang L, et al. Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration. Cell Discov. 2018;4:50. 1
   PubMedGoogle Scholar
• Sugita S, Mandai M, Hirami Y, et al. HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration. J Clin Med. Jul 13 2020;9(7)
   Web of Science ®Google Scholar
• Da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol. Apr 2018;36(4):328–337.
   PubMed Web of Science ®Google Scholar
• Kashani AH, Lebkowski JS, Rahhal FM, et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Transl Med. Apr 4 2018;10(435) eaao4097
   PubMed Web of Science ®Google Scholar
• Mandai M, Watanabe A, Kurimoto Y, et al. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. N Engl J Med. Mar 16 2017;376(11):1038–1046.
   PubMed Web of Science ®Google Scholar
• Kanemura H, Go MJ, Shikamura M, et al. Tumorigenicity studies of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration. PLoS One. 2014;9(1):e85336.
   PubMed Web of Science ®Google Scholar
• Williamson B Gene therapy. Nature. Jul 29 1982;298(5873):416–418.
   PubMed Web of Science ®Google Scholar
• Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. Aug 26 2017;390(10097):849–860.
   PubMed Web of Science ®Google Scholar
• Cashman SM, Ramo K, Kumar-Singh R A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PloS One. 2011;6(4):e19078–e19078.
   PubMed Web of Science ®Google Scholar
• Lueck K, Wasmuth S, Williams J, et al. Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye (Lond). Aug 2011;25(8):1074–1082.
   PubMed Web of Science ®Google Scholar
• Tong JP, Yao YF Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. Clin Biochem. Mar 2006;39(3):267–276.
   PubMed Web of Science ®Google Scholar
• O’Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. Oct 21 1994;79(2):315–328.
   PubMed Web of Science ®Google Scholar
• O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. Jan 24 1997;88(2):277–285.
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Nguyen QD Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). Jul 2013;27(7):787–794.
   PubMed Web of Science ®Google Scholar
• Ramos MS, Xu LT, Singuri S, et al. Patient-Reported Complications after Intravitreal Injection and Their Predictive Factors. Ophthalmol Retina. Oct 12 2020; doi:10.1016/j.oret.2020.09.024
   PubMedGoogle Scholar
• Darrow JJ Luxturna: FDA documents reveal the value of a costly gene therapy. Drug Discov Today. 2019 01 04 2019;24(4):949–954.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Windsor MA, Feuer WJ, et al. Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration. Am J Ophthalmol. Jul 2018;191:135–139.
   PubMed Web of Science ®Google Scholar
• Lee AY, Butt T, Chew E, et al. Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data. Br J Ophthalmol. Apr 2018;102(4):465–472.
   PubMed Web of Science ®Google Scholar
• Rein DB, Saaddine JB, Wittenborn JS, et al. Cost-effectiveness of vitamin therapy for age-related macular degeneration. Ophthalmology. Jul 2007;114(7):1319–1326.
   PubMed Web of Science ®Google Scholar
• Medicare PS Spending on Anti-Vascular Endothelial Growth Factor Medications. Ophthalmol Retina. Aug 2018;2(8):785–791.
   PubMedGoogle Scholar
• Köberlein J, Beifus K, Schaffert C, et al. The economic burden of visual impairment and blindness: a systematic review. BMJ Open. 2013;3(11):e003471–e003471.
   PubMed Web of Science ®Google Scholar
• Kim S, Park SJ, Byun SJ, et al. Incremental economic burden associated with exudative age-related macular degeneration: a population-based study. BMC Health Serv Res. 2019/11/12 2019;19(1):828.
   PubMed Web of Science ®Google Scholar